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Introduction The transition from stable to progressive disease is unpredictable in patients 
with biochemical evidence of medullary thyroid carcinoma (MTC). Calcitonin and 
carcinoembryonic antigen (CEA) doubling times are currently the most reliable markers for 
progression, but for accurate determination serial measurements are required which need time. 
We compared 18F-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET) 
and 18F-dihydroxyphenylanaline (18F-DOPA) PET with biochemical parameters and survival 
to assess whether these imaging modalities could be of value in detecting progressive disease. 
Methods We evaluated outcome of 18F-FDG PET and/or 18F-DOPA PET with calcitonin and 
CEA doubling times in 47 MTC patients. A subgroup of patients was included in whole 
metabolic burden (WBMTB) analysis, with determination of standardized uptake values 
(SUV) and number of lesions. WBMTB of 18F-DOPA PET and 18F-FDG PET was compared 
with biochemical parameters. Furthermore survival was compared with 18F-DOPA PET 
and/or 18F-FDG PET positivity. 
Results In 38 out of 40 patients with 18F-FDG PET doubling times were available. There was 
a significant correlation with 18F-FDG PET positivity. Doubling times were <24 months in 
77% (n=10/13) of 18F-FDG PET positive patients, while 88% (n=22/25) of 18F-FDG PET 
negative patients had doubling times >24 months (p<0.001). Between doubling times and 18F-
DOPA PET positivity no significant correlation existed. 18F-DOPA PET detected significantly 
more lesions (75%, 56 of 75) compared to 18F-FDG PET (47%, 35 of 75) in the 21 patients 
included in WBMTB analysis (p=0.009). Calcitonin and CEA levels correlated significantly 
with WBMTB on 18F-DOPA PET but doubling times did not. 18F-FDG PET positivity was a 
more important indicator for poor survival in patients with both scans performed. 
Conclusion 
18F-FDG PET is superior in detecting patients with biochemical progressive 
disease and identifying patients with a poor survival. Although 18F-DOPA PET has less 
prognostic value it can more accurately assess the extent of the disease in patients with 
residual MTC. Hence, both scans are informative regarding tumour localization and 
behaviour. Based on these results we designed a clinical flow diagram for the general practice 
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Medullary thyroid carcinoma (MTC) accounts for about 4% of all thyroid cancers. The 
overall 10 year survival ranges between 40% and 80% and has not increased substantially in 
the past few decades.1-3 Unfortunately, even in MTC that is clinically confined to the neck, 
many patients already have metastatic disease and are beyond cure even by surgery. 
Furthermore, though the overall survival in patients with only biochemical evidence of 
residual MTC is good, a number of patients will develop progressive and symptomatic 
disease.4 Early identification of these patients is clinically relevant because appropriate 
therapeutic interventions may delay symptomatic deterioration. However, the transition from 
a stable status to a progressive disease course is unpredictable and it is hard to identify 
patients who may benefit from early intervention. 
 Calcitonin is a specific tumour marker for MTC, carcinoembryonic antigen (CEA) is less 
specific, but can also be useful.5 Currently, short calcitonin and CEA doubling times are 
considered the best available indicators to assess progressive disease, MTC recurrence and 
cancer mortality.6,7 Calcitonin and CEA levels can fluctuate, however, and determination of 
the doubling times needs serial measurement for 12-24 months and is therefore time-
consuming. 
 Most imaging techniques have a moderate sensitivity in detecting MTC.8 Positron emission 
tomography (PET) using the radioactive tracers 18F-fluoro-2-deoxy-D-glucose (18F-FDG) and 
more recently 18F-dihydroxyphenylanaline (18F-DOPA) are available for the staging and 
follow-up of MTC.9-15 Some studies have suggested that 18F-FDG PET might be more 
sensitive in patients with a short calcitonin doubling time.16,17 Furthermore, a higher 
metabolic activity, expressed as the maximum standardized uptake value (SUV), on 18F-FDG 
PET compared with the maximum SUV on 18F-DOPA PET, might be related to a more 
aggressive tumour type.18 PET also enables determination of the total tumour load expressed 
as the whole-body metabolic burden (WBMTB), reflecting metabolic tumour activity, as was 
shown in a recent study of 18F-DOPA PET in carcinoid patients.19 
 In this retrospective study of patients with biochemical evidence of MTC, our aim was to 
assess the ability of 18F-FDG PET and 18F-DOPA PET to discriminate between patients with 
progressive disease and patients with stable disease. 
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Materials and methods 
 
Patients 
We analysed all patients with histologically proven MTC seen at the Department of 
Endocrinology for follow-up and who had undergone 18F-FDG PET and/or 18F-DOPA PET 
for detection of residual or metastatic MTC between 2002 and 2010. We excluded patients 
with undetectable calcitonin levels, patients with concurrent systemic treatment at the time of 
18F-FDG PET or 18F-DOPA PET, and patients with less than 2 calcitonin or CEA values at 
the time of 18F-FDG PET or 18F-DOPA PET imaging. For WBMTB analysis, we excluded 
patients with more than 6 months between 18F-FDG PET and 18F-DOPA PET imaging. 
Several patients (n=21) were also described in a previous study assessing the value of 18F-
DOPA PET in patients with MTC.16 That study was approved by the local medical ethics 
committee, and the patients gave written informed consent to participate in it. After 
completion of that study PET was performed as part of standard patient care; therefore in 
concordance with national law no further Institutional Board Review approval was required. 
 We initially analysed 47 MTC patients (Figure 1). In group A, composed of 40 patients, 
18F-FDG PET was performed and we compared outcome with doubling times (n=38) and 
survival (n=37). For the 38 patients composing group B, 18F-DOPA PET was performed, and 
we compared outcome with biochemical parameters (n=36) and survival (n=34).Thirty one 
patients had undergone both scans and in 24 patients these scans were performed within 6 
months of each other. We performed WBMTB and survival analysis in respectively, 21 and 
22 patients (group C), of which 14 and 15 patients respectively, were also included in the 
previous study.16 The number of patients participating in each analysis and reasons for 






F-FDG PET and image analysis 
18F-FDG and 18F-DOPA were locally produced as described previously.20 All patients were 
studied after a 6-h fasting period, were allowed to continue all medication, and were 
encouraged to drink water. For 18F-FDG PET, data acquisition started after 60 or 90 min after 
injection of 18F-FDG intravenously(5 MBq/kg; range 250-824 MBq). For 18F-DOPA PET, 
whole body 2-dimensional-PET images were acquired 60 min after the intravenous 
administration of a standard dose of 18F-DOPA (range 70-220 MBq). To reduce tracer 
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decarboxylation and subsequent renal clearance and thereby increase tracer uptake in tumour 
cells, patients received carbidopa (2 mg/kg; maximum 150 mg) orally as pre-treatment 1 h 
before the 18F-DOPA injection. 
 
 
Figure 1 Flow diagram for inclusion and analysis of MTC patients.*Insufficient biochemical data for calculation 
of doubling times. 
†
Insufficient follow-up data. 
‡
n = 1 without suitable scan for WBMTB analysis due to 
technical problems. pts = patients. 
 
 
18F-FDG PET and 18F-DOPA PET images were interpreted by two dedicated nuclear 
medicine specialists as part of routine patient care and were subsequently independently 
reviewed. We calculated the WBMTB, defined as the sum of the metabolic burden of each 
tumour lesion in the PET image, for both PET methods. We defined metabolic burden as 
mean SUV × volume of tumour lesion obtained from the PET image using a volume of 
interest that was enclosed by a 40 % isodensity contour (Figure 2).21,22 We categorized 
patients according to differences in WBMTB uptake on paired 18F-FDG and 18F-DOPA PET 
scans; more than 10% WBMTB on 18F-FDG PET, more than 10% WBMTB on 18F-DOPA 






Calcitonin was determined using an enzyme-linked immunosorbent assay (Biomerica, Irvine, 
Califorina, USA) with a reference value of 0.3-12 ng/L. CEA levels were measured using a 
chemiluminescent microparticle immunoassay (Abbott Laboratories, North Chicago, Illinois, 
USA) with a reference value of 0.5-5.0 µg/L. 
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Calcitonin and CEA doubling time 
 Calcitonin or CEA <24 mo 
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Calcitonin and CEA serum levels and doubling times 
For calculating the calcitonin and CEA doubling time, we used in principle 4 values (with a 
minimum of 2), obtained within a median period of 11 months (range 2-47 months) around 
18F-FDG PET and 18F-DOPA PET imaging. We used the average of these values for further 
analysis. We calculated exponential growth curves aB, using standard linear regression of the 
serum levels on time and doubling times as ln(2)/B. To identify progressive patients we 
defined biochemical progressive disease as a calcitonin or CEA doubling time of less than 24 
months in concordance with the study of Giraudet et al..6 
 
 
Figure 2  Determination of volume of interest (VOI) and standardized uptake value (SUV) for calculation of the 
whole metabolic burden. On this 
18
F-FDG PET scan four lesions (respectively subcarinal, in the lateral 
hemithorax, and in the liver region) are enclosed by a 40% iso-contour, after manual designation, with 
automatic calculation of SUVmean, SUVmax and lesion volume. 
 
Follow-up 
Follow-up was performed according to current guidelines, consisting of regular determination 
of calcitonin and CEA.23 If there was an elevation in one of these tumour markers, further 
evaluation was performed with morphological or functional imaging. Depending on the 
outcome of imaging, the therapeutic strategy was determined.  
 
Statistical analysis 
For statistical analysis we used PASW statistics 18 (SPSS Ltd.). We performed a χ2 test for 
comparison of PET outcome and doubling times. Correlation between WBMTB of 18F-FDG 
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PET and 18F-DOPA PET and calcitonin or CEA levels and doubling times was calculated 
with Spearman’s r test. To determine the optimal calcitonin cut-off level for 18F-FDG PET 
and 18F-DOPA PET, we calculated the maximum value of sensitivity multiplied by specificity, 
as derived from ROC curve analysis. We performed a χ2 test for comparison of uptake and 
WBMTB category with doubling times or a Fisher exact test when the frequency of cells with 
an expected value of 5 was higher than 20%. For comparison of the number of detected 
lesions between 18F-FDG PET and 18F-DOPA PET, a McNemar test was used. For survival 
analysis we used the Kaplan Meier method, and the log-rank test for comparison. The 






F-FDG PET and biochemical parameters (Group A) 
We analysed 38 patients for outcome of 18F-FDG PET and calcitonin or CEA levels and 
doubling times. 18F-FDG PET was positive in 13 patients (34%) (Table 2). In 18F-FDG PET-
positive patients, levels of calcitonin and CEA were significantly higher and more patients 
had calcitonin and CEA doubling times less than 24 months. Positive and negative predictive 
values for biochemical progressive disease were 77% and 88% respectively in 18F-FDG PET-
positive and -negative patients. In ROC curve analysis, we found an optimal calcitonin cut-off 
of 874 ng/L for PET positivity, with a sensitivity of 69% and a specificity of 70% for the 
detection of tumour lesions. 
 
18
F-DOPA PET and biochemical parameters (Group B) 
Of the 36 patients analysed for the outcome of 18F-DOPA PET and biochemical parameters, 
18F-DOPA PET was positive in 16 (44%) (Table 3). Calcitonin and CEA levels differed 
significantly between 18F-DOPA PET positive and -negative patients, but there was no 
significant difference in doubling times. The positive and negative predictive values for 
progressive disease were 56% and 75%, respectively, in 18F-DOPA PET-positive and -
negative patients. In ROC curve analysis, we found a calcitonin cut-off of 825 ng/l to be 
optimal for PET positivity, with a sensitivity and specificity of 88% and 80%, respectively, 
for detection of tumour lesions. 
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Positive (n = 13) 
18
F-FDG PET  








(60.4 – 161,275) 
 
246 














Calcitonin doubling time 
 < 24 mo 










CEA doubling time 
 < 24 mo 










Calcitonin and CEA doubling time 
 Calcitonin or CEA < 24 mo 










Mo = months. 
 
Table 3 Biochemical parameters of patients with 18F-DOPA PET (Group B) 
*Of 1 pt CEA level was not available. 
†
Of 1 pt CEA dt could not be calculated. mo = months. 
 
WMBTB results of 
18
F-FDG PET and 
18
F-DOPA PET (Group C) 
For the 21 patients with both 18F-FDG PET and 18F-DOPA PET who were included in 
WBMTB analysis, the results for both scans were negative in 11 patients. Of the remaining 10 
patients, 4 had higher WBMTB on 18F-FDG PET, another 4 had higher WBMTB on 18F-
DOPA PET, and 2 had equal WBMTBs (Table 4). The total number of lesions found was 75, 
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18
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(88 – 240,325) 
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(1.2 – 2620) 
6.6 
(0.5 – 72) 
 
<0.001 
Calcitonin doubling time 
 < 24 mo 










CEA doubling time 
 < 24 mo 










Calcitonin and CEA doubling time 
 Calcitonin or CEA < 24 mo 












(p=0.009). In PET-positive patients, WBMTB on 18F-DOPA PET was significantly correlated 
with calcitonin levels (r=0.82) (p=0.013) and CEA levels (r=0.88) (p=0.004) but not with 
doubling times. There was no significant correlation between WBMTB of 18F-FDG PET and 
calcitonin and CEA levels or doubling times. Between the different WBMTB categories and 
calcitonin and CEA doubling times, no significant relation was found. 
 
Table 4 Biochemical parameters and WBMTB in different WBMTB categories (Group C)  



















































Calcitonin and CEA doubling time 
 Calcitonin or CEA < 24 mo 
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  Range 
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F-DOPA 
  Median 




0 – 121 
 
271.6 




18.8 - 920 
 
6.1  




11.5 – 538 
 
271 












Treatment based on PET  
Eight patients underwent reoperation because of recurrent disease. In 5 patients, PET showed 
local disease and contributed to the decision for surgery. 18F-FDG PET was performed in 4 
and positive in 2. 18F-DOPA PET was performed in 4 patients and positive in 3. All PET 
lesions were confirmed on histological examination. In the other 3 patients, PET was negative 
and surgery was performed because of positive conventional imaging or palpable 
abnormalities. All patients who underwent reoperation had no clinical progression during 
follow-up (range 6.6–106 months). Seven patients received targeted treatment with tyrosine 
kinase inhibitors. 18F-FDG PET imaging was performed in 6 patients and all showed 
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metastatic disease, 18F-DOPA PET was performed in 5 and showed metastatic disease in 4. 
Three patients developed stable disease. The other 27 patients did not receive surgical or 
systemic treatment during follow-up. 
 
Survival and PET outcome 
In the 42 patients of whom follow-up data were available, median follow-up was 63.8 months 
(range 2.3-114 months). During follow-up 11 patients died: 7 because of progressive MTC, 3 
because of other causes (prostate cancer, oesophageal cancer and sepsis due to perforated 
appendicitis) and in 1 patient for whom the reason of death was unknown. In 37 patients with 
18F-FDG PET imaging and sufficient follow-up, survival was significantly lower in 18F-FDG 
PET positive patients than in 18F-FDG PET negative patients (p<0.001) (Figure 3A). The 
same was true for 18F-DOPA PET positive compared with -negative patients (n=34) 
(p=0.019) (Figure 3B). However, in univariate analysis of patients who had undergone both 
18F-FDG PET and 18F-DOPA PET (n=22), the survival in patients with a positive 18F-FDG 
PET was lower and independent of 18F-DOPA PET outcome, whereas survival in 18F-DOPA 
PET positive patients was dependent of 18F-FDG PET outcome (p=0.018) (Figure 3C). Figure 
4 shows a patient with biochemical progressive disease and uptake on both scans.  
 










Figure 4  MTC patient with uptake on both 18F-DOPA PET (left) and 18F-FDG PET (right). On 18F-DOPA-PET 
lesions are seen in the right supraclavicular region, the right hemithorax and there is slight uptake subcarinal. In 
the abdomen there are several lesions with faint uptake. Also on 
18
F-FDG-PET uptake is seen in the right 
supraclavicular region, right hemithorax and intensive uptake subcarinal. Furthermore several lesions are seen 
in the liver region. Calcitonin and CEA levels were highly elevated (23236 ng/L (ref 0.3-12 ng/L) and 2144 ug/L 
(ref 0.5-5.0 μg/L)) and calcitonin and CEA doubling times were short; 13 months and 12 months respectively. 




In this study, 18F-FDG PET was superior to 18F-DOPA PET in identifying patients with 
progressive disease. Unlike 18F-DOPA PET positivity, 18F-FDG PET positivity correlated 
significantly with biochemical progressive disease. Furthermore, we showed that 18F-FDG 
PET- and 18F-DOPA PET positive patients, had a significantly decreased survival. However, 
univariate analysis in patients for whom both scans were performed showed that 18F-FDG 
PET positivity had the most influence on survival. WBMTB analysis showed that metabolic 
activity on 18F-DOPA PET correlated significantly with calcitonin and CEA levels. 
Differences (>10%) in WBMTB on 18F-FDG PET and 18F-DOPA PET could not distinguish 
stable from progressive disease.  
 In a previous study of our institute focusing on detecting residual disease with both 18F-
FDG PET and 18F-DOPA PET, we already described the superiority of 18F-FDG PET in 2 
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patients with progressive disease.16 This outcome is probably based on the fact that aggressive 
(dedifferentiated) disease has a higher glucose metabolism and consequently higher 18F-FDG 
uptake. This observation was also made by others but the described series are rather 
small.14,15,17,18 Bogsrud et al. showed a higher mortality in 18F-FDG PET positive patients than 
in 18F-FDG PET negative patients.24 However, survival data in patients with 18F-DOPA PET 
have not been described before. This study shows that progressive patients can be identified 
with both PET techniques, taking into account biochemical parameters and survival.  
 For 18F-FDG PET of patients with progressive MTC, not only have higher sensitivities  
been described but also increased tracer intensity. Marzola et al. included only patients with 
short doubling times (6-9 months) and showed significantly higher maximum SUV on 18F-
FDG PET versus 18F-DOPA PET, although patient- and lesion-based sensitivity of 18F-DOPA 
PET was higher.18 In our WBMTB analysis, we did not find a significant difference in 
doubling times between patients with a higher uptake on 18F-FDG PET and patients with a 
higher uptake on 18F-DOPA PET. This lack of significance could have been caused by the 
small number of patients with positive scan results in WBMTB analysis (n=11) or the 
different doubling time cut-offs used for defining progressive disease. 
 Although the doubling times of calcitonin and CEA have thus far been the most reliable 
indicators of recurrence and progressive disease in MTC, cut-off values are still a matter of 
discussion. Meijer et al. showed a higher hazard ratio for recurrence for a calcitonin doubling 
time cut-off of 12 months (hazard ratio, 5.33) than 24 months (hazard ratio, 2.93), but warned 
about interpreting these cut-off values with caution.7 Moreover that study focuses on disease 
recurrence and not progression in general. We based our 24 months cut-off for doubling times 
on the results of the study by Giraudet et al., who compared doubling times with progression 
according to the Response Evaluation Criteria in Solid Tumours (RECIST). They found 
progressive disease in 94% of patients with doubling times less than 25 months while 86% 
had stable disease when doubling times were more than 24 months.6 
 Our results show a significant correlation between WBMTB on 18F-DOPA PET and 
calcitonin and CEA levels, demonstrating that 18F-DOPA PET might be a good indicator of 
tumour load. Although 18F-FDG PET is better in distinguishing progressive disease, 18F-
DOPA PET seems to be more important in assessing the extent of residual disease. In our 
WBMTB analysis, 18F-DOPA PET also detected more tumour lesions than did 18F-FDG PET. 
On the whole, 18F-DOPA PET is superior to 18F-FDG PET with a higher patient-based 
sensitivity (64% vs. 48%, respectively [range, 38%-83% vs. 17%-64%, respectively]) and 
lesion-based sensitivity (72% vs 52%, respectively [range 52%-94% vs. 28%-62%]) (Table 
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5).12-15,17,18 However, in line with the study of Kauhanen et al. and a recent review by Wong et 
al., combining both modalities increases sensitivity and is complementary.14,25 
 Nevertheless, many patients with biochemical recurrent disease do not show lesions on 
currently available imaging modalities. Most of these patients have moderately elevated 
tumour markers and long doubling times, probably because of the nature of calcitonin-
producing metastases (sclerotic, necrotic or calcified) and their small size.26 A previous study 
of our centre showed that MTC lesions are best detected on 18F -DOPA PET above >500 ng/L 
and ROC curve analysis in the current study found a cut-off value of 825 ng/l to be optimal in 
distinguishing 18F -DOPA PET-positive from -negative patients.16 This cut-off value is also 
dependent on the resolution of the PET camera system, which with new developments 
becomes increasingly sensitive. Also, the combination of PET with CT increases the yield of 
these scans and lowers the threshold for localization of tumour lesions.27 
 The negative predictive value for biochemical progressive disease in our study was 88% 
for 18F-FDG PET and 75% for 18F-DOPA PET. However, there are still patients - both in our 
study (n=3) and in other series – who have rapidly increasing tumour markers but do not have 
positive functional imaging results.18 In these patients, there is still need for other modalities 
for the detection of occult MTC. Yet, the first results of new tracers like 68Ga-somatostatin 
analogues or 11C-Methionine are not convincing.15,28,29 
 
Table 5 Patient and lesion based sensitivity of 18F-FDG PET and 18F-DOPA PET.  











Hoegerle et al. 2001 11 64% (7) 64% (7) 73% (8) 27 44% (12) 63% (17) 
Beuthien-Baumann et 
al. 2007 
15 47% (7) 47% (7) 60% (9) NA NA NA 
Beheshti et al. 2009  26 58% (15) 81% (21) 85% (22) 53 62% (33) 94% (50) 
Marzola et al. 2010  18 61% (11) 83% (15) 89% (16) 111 58% (64) 76% (84) 
Kauhanen et al. 2011  19 53% (10) 58% (11) 63% (12) 118 47% (55) 52% (61) 
Treglia et al. 2012  18 17% (3) 72% (13) 72% (13) 72 28% (20) 85% (61) 
This study 21
‡
 38% (8) 38% (8) 48% (10) 75 47% (35) 75% (56) 
Total 128 48% (61) 64% (82) 70% (90) 456 48% (219) 72% (329) 
*Average calcitonin, median not available. 
†
Only 19 pts with data available. 
‡
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On the basis of the results of this and previous studies, we recommend a combined approach 
for patients with recurrent MTC and increasing tumour markers (Figure 5). Conventional 
imaging of the neck (ultrasound, MRI or CT) to detect localized disease can be followed by 
18F-FDG PET or PET/CT to identify progressive disease. In the case of a negative 18F-FDG 
PET result or the presence of only localized resectable disease (head and neck region), an 18F-
DOPA PET or PET/CT scan is recommended, to exclude distant metastasis and support the 
decision for local surgery.  
 
  
Figure 5  Flow-diagram for combined approach of 18F-FDG PET and 18F-DOPA PET in patients with recurrent 
MTC and increasing tumour markers. If 
18
F-FDG PET or 
18
F-DOPA PET shows distant metastatic disease, targeted 
therapy can be considered. If there is resectable localized disease on 
18
F-FDG PET or 
18
F-DOPA PET, with an 
anatomical substrate, surgery could be considered. If both 
18
F-FDG PET and 
18
F-DOPA PET are negative, follow-





This study is limited by its retrospective character and the differences in 18F-FDG PET uptake 
time, which can result in differences in the mean SUV. Most of our patients who were 
included in the WBMTB analysis had an uptake time of 60 min (n=16). Because the WBMTB 
for determination of tumour load depends not only on the mean SUV but also on tumour 
volume and number of lesions we concluded that a slight difference in mean SUV does not 
significantly influence our results. Furthermore, there could be a selection bias in patients 
undergoing only 1 type of scan, or both scans. However, no significant difference existed in 
patient characteristics (including doubling times) between these 2 groups (data not shown). 
Other limitations are the small study size, which is often the case with rare tumours, and the 




In MTC patients, 18F-FDG PET positivity seems to be associated with biochemical 
progressive disease and significantly affects survival. 18F-DOPA PET has a higher sensitivity 
than 18F-FDG PET, and WBMTB on 18F-DOPA PET can be related to the tumour load. 
Therefore, 18F-DOPA PET seems to be more important in assessing the extent of the disease 
in patients with residual disease whereas 18F-FDG PET can more accurately identify patients 
with progressive disease. Both scans may be used to guide therapeutic strategies in patients 
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